GHO and Ampersand Capital to acquire Avid Bioservices
The definitive merger agreement stipulates that GHO and Ampersand will purchase all outstanding shares of Avid.
Avid Bioservices to be acquired for $1.1B in cash by GHO, Ampersand
Avid Bioservices (CDMO) has agreed to be acquired by GHO Capital Partners and Ampersand Capital Partners through a cash deal that values the company at $1.1B. Read more here.
Avid Bioservices to go private in $1.1bn private equity deal
The $12.50-per-share takeover has been approved by Avid's board and is scheduled to close in the first quarter of 2025, subject to Avid shareholder approval and meeting the usual regulatory conditions. Shares in the company rose 4% after the deal was announced and another 12% in after-hours trading.
Avid Bioservices to be taken private by GHO, Ampersand in $1.1 billion deal
Avid Bioservices said on Wednesday that it would be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners in a deal valued at about $1.1 billion. GHO and Ampersand have offered $12.
GHO Capital, Ampersand Capital to buy Avid Bioservices in $1.1bn deal
GHO Capital Partners and Ampersand Capital Partners have agreed to acquire Avid Bioservices, a biologics contract development and manufacturing organization, in an all-cash transaction valued at around $1.1 billion. Avid provides development and manufacturing services to biotechnology and pharmaceutical companies. It is based in Tustin, California.
Avid Bioservices to Go Private in $1.1 Billion Deal
Avid Bioservices Chief Executive Nick Green said the company’s board considered several options before determining to move forward as a private company under new owners.
Avid Bioservices to be Acquired in $1.1 Billion Deal
Avid Bioservices ( (CDMO) ) just unveiled an announcement. Avid Bioservices, a biologics contract development and manufacturing organization,
FiercePharma15h
Biologics CDMO Avid Bioservices to go private with $1.1B sale to Ampersand, GHO Capital
Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...
TMCnet23m
Shareholder Alert: Ademi LLP Investigates Whether Avid Bioservices, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Ademi LLP is investigating Avid (NASDAQ: CDMO) for possible breaches of fiduciary duty and other violations of law in its transaction with GHO and Ampersand. Click here to learn how to join our ...
Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Transaction
Under the terms of the merger agreement, GHO and Ampersand would acquire all the outstanding shares held by Avid’s stockholders for $12.50 per share in cash. The per share purchase price represents a ...
Business Wire5h
CDMO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avid Bioservices, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avid Bioservices, Inc. (NASDAQ: CDMO) to ...
MM&M16h
Rx Rundown: Avid Biosciences, Novo Nordisk, Zealand Pharma and more
Nektar Therapeutics is selling its Huntsville, Alabama, manufacturing plant and reagent supply business to private equity firm Ampersand Capital Partners for $90 million. Ascendis Pharma and Novo ...
PharmTech9h
Avid Bioservices Acquired by GHO Capital Partners and Ampersand Capital Partners
The merger agreement is valued at approximately $1.1 billion. Avid Bioservices, a biologics contract development and manufacturing organization (CDMO), announced on Nov. 6, 2024 that it has entered ...